Dr. Lara on Epacadostat Plus Pembrolizumab in RCC
June 23rd 2017
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).